EP4403168A1 — Fixed-dose combination composition of metformin and empagliflozin
Assigned to Adamed Pharma SA · Expires 2024-07-24 · 2y expired
What this patent protects
A fixed-dose pharmaceutical preparation in the form of a coated tablet for oral administration comprising extended release metformin hydrochloride as the core of the tablet, coated with an intermediate coating based on hydroxypropylmethylcellulose as a film-forming material, furt…
USPTO Abstract
A fixed-dose pharmaceutical preparation in the form of a coated tablet for oral administration comprising extended release metformin hydrochloride as the core of the tablet, coated with an intermediate coating based on hydroxypropylmethylcellulose as a film-forming material, further coated with empagliflozin comprising active coating based on partially hydrolyzed polyvinyl alcohol as a film-forming material, and further optionally coated with outer protective coating.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.